LOS ANGELES, Jan. 18 (Xinhua) -- A U.S. investigational HIV vaccine regimen was safe but did not provide protection against HIV acquisition, according to a release of the U.S. National Institute of Health (NIH) on Wednesday.
The trial, called HPX3002/HVTN 706 or "Mosaico," began in 2019 and involved 3,900 volunteers ages 18 to 60 years in Europe, North America and South America.
